These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8911006)

  • 41. Tolerability and immunogenicity of a polyvalent Pseudomonas aeruginosa extract vaccine in human volunteers.
    Martindale JJ; Ganzinger U; Steinmüller W; Millendorfer A; Ambrosch F; Kollaritsch H; Wiedermann G
    Zentralbl Bakteriol Mikrobiol Hyg A; 1988 May; 268(3):376-85. PubMed ID: 3136608
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase 1 trial of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously.
    Edelman R; Taylor DN; Wasserman SS; McClain JB; Cross AS; Sadoff JC; Que JU; Cryz SJ
    Vaccine; 1994 Nov; 12(14):1288-94. PubMed ID: 7856293
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Protective efficacy of recombinant exotoxin A--flagellin fusion protein against Pseudomonas aeruginosa infection.
    Farajnia S; Peerayeh SN; Tanomand A; Majidi J; Goudarzi G; Naghili B; Rahbarnia L
    Can J Microbiol; 2015 Jan; 61(1):60-4. PubMed ID: 25496361
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [[Vaccine development for P. aeruginosa: based on antigen cloning of clinical vaccines][].
    von Specht BU
    Zentralbl Chir; 1999; 124(4):298-302. PubMed ID: 10355084
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans.
    Cryz SJ; Sadoff JC; Fürer E; Germanier R
    J Infect Dis; 1986 Oct; 154(4):682-8. PubMed ID: 3091708
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunity of cattle following vaccination with a Mannheimia haemolytica chimeric PlpE-LKT (SAC89) protein.
    Confer AW; Ayalew S; Montelongo M; Step DL; Wray JH; Hansen RD; Panciera RJ
    Vaccine; 2009 Mar; 27(11):1771-6. PubMed ID: 18834912
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification and immunogenicity of Mannheimia haemolytica S1 outer membrane lipoprotein PlpF.
    Ayalew S; Shrestha B; Montelongo M; Wilson AE; Confer AW
    Vaccine; 2011 Nov; 29(47):8712-8. PubMed ID: 21875637
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunogenicity in adult males of a Neisseria meningitidis group B vaccine composed of polysaccharide complexed with outer membrane proteins.
    Lifely MR; Roberts SC; Shepherd WM; Esdaile J; Wang Z; Cleverly A; Aulaqi AA; Moreno C
    Vaccine; 1991 Jan; 9(1):60-6. PubMed ID: 1901187
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model.
    DiGiandomenico A; Rao J; Goldberg JB
    Infect Immun; 2004 Dec; 72(12):7012-21. PubMed ID: 15557624
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group.
    Schlesinger Y; Granoff DM
    JAMA; 1992 Mar; 267(11):1489-94. PubMed ID: 1538539
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.
    Cryz SJ; Fürer E; Cross AS; Wegmann A; Germanier R; Sadoff JC
    J Clin Invest; 1987 Jul; 80(1):51-6. PubMed ID: 3110215
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Conformation-dependent antibody response to Pseudomonas aeruginosa outer membrane proteins induced by immunization in humans.
    Lee N; Ahn B; Jung SB; Kim YG; Kim H; Park WJ
    FEMS Immunol Med Microbiol; 2000 Jan; 27(1):79-85. PubMed ID: 10617794
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.
    Zaidi TS; Priebe GP; Pier GB
    Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intranasal administration of a Pseudomonas lipopolysaccharide vaccine in cystic fibrosis patients.
    Wood RE; Pennington JE; Reynolds HY
    Pediatr Infect Dis; 1983; 2(5):367-9. PubMed ID: 6415621
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bioengineering a bacterial pathogen to assemble its own particulate vaccine capable of inducing cellular immunity.
    Lee JW; Parlane NA; Wedlock DN; Rehm BH
    Sci Rep; 2017 Feb; 7():41607. PubMed ID: 28150705
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vaccines against Pseudomonas aeruginosa infection: 2. Clinico-immunological investigations.
    Krokhina MA; Grishina IA; Panova YuM ; Terekhova RP; Severtsova MK; Yedvabnaya LS; Vaide M; Varro R; Rusanov VM; Kolker II
    Vaccine; 1985 Sep; 3(3):316-24. PubMed ID: 3933202
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Outpatient studies of the safety and immunogenicity of an auxotrophic Escherichia coli K-12-Shigella flexneri 2a hybrid vaccine candidate, EcSf2a-2.
    Taylor DN; Phillip DF; Zapor M; Trofa A; Van de Verg L; Hartman A; Bendiuk N; Newland JW; Formal SB; Sadoff JC
    Vaccine; 1994 May; 12(6):565-8. PubMed ID: 8036831
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study.
    Malfertheiner P; Selgrad M; Wex T; Romi B; Borgogni E; Spensieri F; Zedda L; Ruggiero P; Pancotto L; Censini S; Palla E; Kanesa-Thasan N; Scharschmidt B; Rappuoli R; Graham DY; Schiavetti F; Del Giudice G
    Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):698-707. PubMed ID: 30042064
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [An acellular vaccine from Pseudomonas aeruginosa. II. -- Estimate of immuneserum protective effect by measure of bacterial clearance (author's transl)].
    Daoulas-Le Bourdelles F; Berche P; Véron M
    Ann Microbiol (Paris); 1977 Jul; 128B(1):61-71. PubMed ID: 410340
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model.
    Matthews-Greer JM; Gilleland HE
    J Infect Dis; 1987 Jun; 155(6):1282-91. PubMed ID: 3033095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.